TP53 and breast carcinoma: Inhibitory concentrations IC50[a] [μm] of test compounds 1 a–q when applied to 518 A2 melanoma, KB‐V1Vbl MDR cervix carcinoma (treated with and without 1 μm verapamil), U‐87 MG likely glioblastoma, MCF‐7 breast carcinoma, HT‐29, HCT‐116 and HCT‐116p53−/− (p53 knockout mutant) colon carcinoma, EA.hy926 endothelial hybrid cells, and HDFa human dermal fibroblasts.